Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

The S&P 500 Index ($SPX) (SPY) today down -0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.44%, and the ...

Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...

Governor Greg Abbott joined Chief of the National Guard Bureau and member of the Joint Chiefs of Staff General Steven ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...